Abstract
The tall-cell variant of papillary thyroid carcinoma is a rare malignancy characterized by an aggressive course, low relapse-free survival, early metastasis, and frequent development of radioiodine refractoriness. We report two cases of tall-cell papillary thyroid carcinoma in patients who had disease progression after combination treatment and started to receive lenvatinib. We observed partial and complete regression of metastases in response to lenvatinib. Our findings are consistent with the results of other studies assessing treatment efficacy for disseminated tall-cell papillary thyroid carcinoma.
Highlights
Tall-cell variant of papillary thyroid carcinoma: literature review and case reports Е
Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; 4 Koroleva St., Obninsk 249036, Russia The tall-cell variant of papillary thyroid carcinoma is a rare malignancy characterized by an aggressive course, low relapse-free survival, early metastasis, and frequent development of radioiodine refractoriness
We report two cases of tall-cell papillary thyroid carcinoma in patients who had disease progression after combination treatment and started to receive lenvatinib
Summary
Tall-cell variant of papillary thyroid carcinoma: literature review and case reports Е. В их исследовании у пациентов с ПРЩЖ из высоких клеток без экстратиреоидного распространения наблюдалась значительно более высокая частота метастатического поражения регионарных лимфатических узлов, чем у пациентов с классическим вариантом ПРЩЖ также без экстратиреоидного распространения, причем независимо от возраста, пола и размера опухоли (р = 0,004). Средний возраст 278 пациентов с ПРЩЖ из высоких клеток был больше, чем у пациентов с классическим вариантом (соответственно 54,3 и 46,3 года, р
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
